Resteaze: a novel wearable device and mobile application to improve the diagnosis and management of restless legs syndrome in patients with alzheimer's disease
Ended Project Grant Awarded Last action
- Award ID
- R43AG076092
- Recipient
-
Tanzen Medical, Inc. UEI CYU5N7VNCPN3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,112,836
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Funding
-
- $1,612,127.00 Federal
- $500,709.00 Non-federal
- Place of performance
- Severna Park, MD 21146, USA
Award details come from USAspending.gov.
Description
- Abstract
- Millions of patients with alzheimer's disease (ad) suffer from sleep disturbances that significantly degrade their quality of life and amplifies the heavy emotional burden on caregivers. Restless legs syndrome (RLS) is likely a factor for the sleep disturbance in these patients, however, RLS is currently difficult to diagnose, particularly in patients with ad. The diagnosis is made clinically with subjective, patient reports and the symptoms themselves are variable across individuals. Thus, patients with ad who may already have difficulty with verbal expression are especially vulnerable to being misdiagnosed. Furthermore, recent studies suggest that nighttime agitations (a particularly troublesome symptom of ad that leads to early institutionalization) may be a manifestation of undiagnosed and therefore unmanaged RLS. Resteaze is an ankle-worn wearable technology and mobile application developed by tanzen medical INC to measure leg movements during sleep that are highly related to RLS and can serve as an objective biomarker of the condition. The device is industrially designed to be comfortably worn by the patient and washable to permit extended, nightly use. The mobile application is easy to use by the patient (or caregiver) to interact with and store data from the device. The read-out provided to the clinician provides clear, actionable information that quantifies the patients' leg movements during sleep in reference to american academy of sleep medicine standards. In SUM, resteaze directly addresses a significant unmet medical need by providing a technology that can substantially improve the diagnosis and subsequent management of RLS in patients with ad. The use of this technology is expected to improve the quality of life for patients with ad and their caregivers by directly addressing their sleep disturbance and preventing the need for early institutionalization or other ancillary medical services.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $55,000 | $0 | |
| Amendment | $55,000 | $0 | |
| Amendment | $500,709 | $0 | |
| Amendment | $500,709 | $500,709 | |
| Original award | $500,709 | $0 |
Quick answers
Who received award R43AG076092?
R43AG076092 was awarded to Tanzen Medical, Inc. by National Institute on Aging (National Institutes of Health) on March 15, 2022.
How much is award R43AG076092 worth?
$2,112,836 has been obligated on R43AG076092: $1,612,127 in federal funding and $500,709 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award